Wednesday, February 23, 2022

Avivagen Inc. (VIVXF)(VIV:CA)
Receives Approval for OxC-beta in Vietnam

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Vietnam Approval. Yesterday, Avivagen announced a major milestone with the approval for use of OxC-beta in Vietnam. Vietnam represents the largest feed market in Southeast Asia, according to a report by the US Grains Council, which indicates total annual feed consumption of over 32 MMT in 2020. Additionally, the Grains Council report states that Vietnam is a strong growth market which is expected to surpass 35 MMT of feed within the next few years.


Research Trials.  The use of Avivagen’s product in the Vietnam feed industry is supported by the positive results of two research trials conducted specifically under Vietnamese commercial production conditions. The trials were run in collaboration with the Institute for Animal Sciences for South Vietnam and were conducted with pigs. Notably, the African Swine Flu is transforming the Vietnam swine …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.